New hope for tough lymphoma: experimental drug shows promise

NCT ID NCT03494179

Completed Disease control Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 10, 2026 · Last updated Jun 11, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ICP-022 in 106 adults with mantle cell lymphoma that had come back or stopped responding to prior treatments. The goal was to see if the drug could shrink tumors and to check its safety. The approach focuses on controlling the disease rather than curing it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Anhui Province Cancer Hospital

Hefei, Anhui, 230009, China
Beijing Cancer Hospital

Beijing, Beijing Municipality, 102206, China
Fujian Medical University Union Hospital

Fuzhou, Fujian, 350001, China
Guangzhou First People's Hospital

Guangzhou, Guangdong, 510180, China
Henan Provincial People's Hospital

Zhengzhou, Henan, 450003, China
Henan Tumor Hospital

Zhengzhou, Henan, 450008, China
Jiangsu Province Hospital

Nanjing, Jiangsu, 210029, China
Jilin Cancer Hospital

Changchun, Jilin, 130012, China
Liaoning Cancer Hospital and Institute

Shenyang, Liaoning, 110042, China
Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China
Peking University Third Hospital

Beijing, Beijing Municipality, 100191, China
Qilu Hosptial of Shandong University

Jinan, Shandong, 250012, China
Shandong Provincial Hospital

Jinan, Shandong, 250021, China
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China
The Affiliated Hospital of Qingdao University

Qingdao, Shandong, 266071, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325000, China
The First Affiliated Hospital of Xiamen University

Xiamen, Fujian, 361003, China
The First Affiliated Hospital of Zhengjiang University

Hangzhou, Zhejiang, 310003, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450052, China
The First Hospital of China Medical University

Shenyang, Liaojing, 110001, China
The First Hospital of Jilin University

Changchun, Jilin, 130021, China
The Fourth Hospital of Hebei Medical University

Shijiazhuang, Hebei, 050011, China
The Second Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310052, China
The Second Hospital of Dalian Medical University

Dalian, Liaoning, 116044, China
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China
Tongji Hospital

Wuhan, Hubei, 430030, China
West China Hospital,Sichuan University

Chengdu, Sichuan, 610041, China
Wuhan Union Hospital

Wuhan, Hubei, 430022, China
Xin Hua Hospital Affiated to Shanghai Jiao Tong University School of Medicin

Shanghai, Shanghai Municipality, 200092, China
Zhejiang Cancer Hospital

Hangzhou, Zhejiang, 310022, China
Zhongshan Hospital

Shanghai, Shanghai Municipality, 200032, China

Conditions

Explore the condition pages connected to this study.

MANTLE CELL LYMPHOMA

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA